SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
The new ECO grade is made using renewable feedstock
The product has been in-licensed from Strides and will be commercialized by Amneal
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Prior to this, Jim held leadership positions at several companies, including Centrient Pharmaceuticals, Leo Pharmaceuticals, Sandoz, Xellia, and GSK
Subscribe To Our Newsletter & Stay Updated
